Technical Analysis for NSPX - Inspyr Therapeutics Inc.

Grade Last Price % Change Price Change
grade B 0.0046 21.05% 0.0008
NSPX closed up 21.05 percent on Tuesday, August 20, 2019, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
0 Watchers
Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical NSPX trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
MACD Bearish Signal Line Cross Bearish 21.05%
Narrow Range Bar Range Contraction 21.05%
Wide Bands Range Expansion 21.05%

Older signals for NSPX ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:
Profile
Inspyr Therapeutics, Inc., formerly GenSpera, Inc., is an early-stage pharmaceutical company. The Company is focused on the development of prodrug cancer therapeutics for the treatment of solid tumors, including liver, brain, prostate, renal and other cancers. Its technology platform combines a plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that targets the release of the drug within the solid tumor. Its cancer prodrugs provide a targeted therapeutic approach to a range of solid tumors. Its product candidates include Mipsagargin, G-115, G-114 and G-301. Its lead drug candidate, mipsagargin, is activated by the enzyme prostate specific membrane antigen (PSMA), which is found in prostate epithelial cells in the normal prostate, in prostate cancer cells, and in vascular endothelial cells (blood vessels) found in solid tumors. Mipsagargin is in Phase II clinical evaluation in glioblastoma patients.
Chemistry RTT Cancer Pharmaceutical Biology Solid Tumors Prostate Cancer Glioblastoma Solid Tumor Northwest Biotherapeutics Cancer Therapeutics
Is NSPX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
See more NSPX news...
Indicators
Indicator Value
52 Week High 0.0131
52 Week Low 0.0022
Average Volume 422,125
200-Day Moving Average 0.0048
50-Day Moving Average 0.0042
20-Day Moving Average 0.0047
10-Day Moving Average 0.0046
Average True Range 0.0008
ADX 18.17
+DI 19.8276
-DI 28.4483
Chandelier Exit (Long, 3 ATRs ) 0.0034
Chandelier Exit (Short, 3 ATRs ) 0.0056
Upper Bollinger Band 0.0056
Lower Bollinger Band 0.0038
Percent B (%b) 0.44
BandWidth 38.297872
MACD Line 0.0001
MACD Signal Line 0.0001
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0064
Resistance 3 (R3) 0.0062 0.0054 0.0061
Resistance 2 (R2) 0.0054 0.0049 0.0055 0.0060
Resistance 1 (R1) 0.0050 0.0047 0.0052 0.0052 0.0059
Pivot Point 0.0042 0.0042 0.0043 0.0043 0.0042
Support 1 (S1) 0.0038 0.0037 0.0040 0.0040 0.0033
Support 2 (S2) 0.0030 0.0035 0.0031 0.0032
Support 3 (S3) 0.0026 0.0030 0.0031
Support 4 (S4) 0.0028